Acumen 505

Acumen 505 is an FDA-cleared, next generation sequencing-based in vitro diagnostic assay to detect single nucleotide variants (SNVs) and small insertions and deletions (indels) in 505 genes, select amplifications and translocations, and genomic signatures including microsatellite instability (MSI), and tumor mutation burden (TMB) from genomic DNA isolated from formalin-fixed paraffin embedded tissue specimens.

Acumen 505 enables rapid and actionable genomic insights for all patients with advanced cancer. Backed by robust bioinformatics, our test rapidly and accurately identifies cancer mutations, empowering oncologists to make timely treatment decisions that optimize outcomes.